Figure 1
Figure 1. C1498.GFP grows progressively when injected intravenously into immunocompetent, syngeneic mice. (A) C57BL/6 mice were injected with 106 C1498.GFP cells on day 0. On days 7, 10, and 13, peripheral blood was drawn from individual mice. Red blood cells were removed via exposure to ACK lysis buffer, and samples were analyzed by flow cytometry. The percentage of leukemia cells was calculated as percentage of GFP+ cells/percentage of total white blood cells. (B) Analysis of survival in a cohort of 5 C57BL/6 mice injected with C1498.GFP IV. Similar results were obtained in 2 independent experiments. (C) FACS analysis of organs from a C57BL/6 mouse 14 days after challenge with C1498.GFP.

C1498.GFP grows progressively when injected intravenously into immunocompetent, syngeneic mice. (A) C57BL/6 mice were injected with 106 C1498.GFP cells on day 0. On days 7, 10, and 13, peripheral blood was drawn from individual mice. Red blood cells were removed via exposure to ACK lysis buffer, and samples were analyzed by flow cytometry. The percentage of leukemia cells was calculated as percentage of GFP+ cells/percentage of total white blood cells. (B) Analysis of survival in a cohort of 5 C57BL/6 mice injected with C1498.GFP IV. Similar results were obtained in 2 independent experiments. (C) FACS analysis of organs from a C57BL/6 mouse 14 days after challenge with C1498.GFP.

Close Modal

or Create an Account

Close Modal
Close Modal